RegeneRx Publishes Regulatory Update on RGN-259

ROCKVILLE, Md., Jan. 12, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published an update regarding the regulatory progress of RGN-259 on the Company's website at

SOURCE RegeneRx Biopharmaceuticals, Inc.

For further information: Lori Smith, 301.208.9191,